biobank.cy: The Biobank of Cyprus past, present and future

Eleni M. Loizidou[1], Maria Kyratzi[1], Maria A. Tsiarli[1], Andrea C. Kakouri[1], Georgia Charalambidou[1], Stella Antoniou[1], Stylianos Pieri[1], Panagiota Veloudi[1], Michaela Th. Mayrhofer[2], Andrea Wutte[2], Lukasz Kozera[2], Jens Habermann[2], Heimo Muller[3], Kurt Zatloukal[3], Karine Sargsyan[3], Alexandros Michaelides[4], Maria Papaioannou[5], Christos Schizas[5], Apostolos Malatras[1], Gregory Papagregoriou[1], Constantinos Deltas[1,6*]

[1]biobank.cy, Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Nicosia, Cyprus.

[2]Biobanking and BioMolecular Resources Research Infrastructure-European Research Infrastructure Consortium (BBMRI-ERIC) Graz, Austria

[3]Diagnostic & Research Institute of Pathology, Medical University of Graz, Graz, Austria

[4]RTD TALOS LTD

[5]Cyprus National e-Health Authority

[6]School of Medicine, University of Cyprus, Nicosia, Cyprus

*Corresponding author:

Prof. Constantinos Deltas

University of Cyprus, School of Medicine

1, University Avenue, 2109 Nicosia

E-mail: Deltas@ucy.ac.cy

Tel: +357 22892882

Abstract

Background: The Cyprus Biobank collects biosamples, medical and lifestyle information with the aim of reaching 16,500 Cypriots aged ≥18-years, by year 2027, as part of a multitasked EU funded project. Volunteers are both from the general population and from disease cohorts of focused research projects, who amongst others will contribute to canvas the architecture of the Cyprus human genome and study the healthy and morbid anatomy of Cypriots. The Cyprus Biobank is a research infrastructure pillar of the biobank.cy Center of Excellence in Biobanking and Biomedical Research.

Methods: Within 3-years (November 2019-October 2022), 1348 participants of the general population who represent a subset of the Cyprus Biobank recruited individuals, were enrolled in the pilot study. The study did not include individuals from separate disease-specific cohorts. Extensive information was collected from each participant, including biochemistry, complete blood count, physiological, anthropometric, socio-demographic, diet, and lifestyle characteristics. Prevalent health conditions along with medication use and family history were recorded, including 58 biomarkers based on blood and urine samples. With a systematic recruitment campaign, the Biobank is continuously increasing the number of individuals in the general population cohort and is developing separate disease cohorts of the Cypriot population.

Results: The pilot study enrolled 579 men and 769 women, aged between 18-85 years (median 48-years). The enrollment takes 40 minutes on average, including the collection of biological samples and phenotypic information. More than half (n=733, 55%) of the participants are educated to college level or above. Statistically significant differences were found between men and women regarding their education level ($p<0.001$), marital status ($p=0.01$) and employment status ($p<0.001$) but not their age ($p=0.29$). The most prevalent medical conditions recorded are hypertension (17.2%), osteoporosis (6.9%) and diabetes (6.0%).

Conclusions: The Cyprus biobanking pilot study has successfully collected extensive baseline information from enrolled participants. The Biobank will comprise a rich data resource used to examine the major risk factors leading to public health burdens and develop strategies for disease prevention.

Keywords: Biobank, Cohort Study, Public Health, Population Health, Non-communicable diseases

Introduction

Cyprus is the third largest island in the Mediterranean Sea and has been at the crossroad of many civilizations over the centuries. Its prestigious strategic location within the southeast corner of the Mediterranean basin, bridging the Middle East and Europe, always attracted foreign rulers that sought to control the area and thereby extend the trade pathways. The island of Cyprus was first inhabited during the aceramic neolithic period by people from the Middle East and Asia Minor, more than 12,000 years ago, according to archeological evidence and genetic phylogeographic investigations[1]. Over the years it was influenced, or was occupied by, several rulers (Table 1), the most recent occupations of which were the Ottoman Empire between the years of 1571-1878, after which it was taken over by the British, 1878-1960. After a liberation struggle, 1955-1959, the Republic of Cyprus was first established as an independent country in 1960, at which time it joined membership to the United Nations. In 2004, Cyprus joined the European Union and in 2008 adopted the Euro currency. The island's recent and mainly older tumultuous history, including major and minor migration waves, has had its contribution to the Cypriot gene pool, as evidenced by several genetic studies performed over the past 30 years [2].

Table 1. Brief report of visitors-conquerors and key events in the history of Cyprus
The Cypriot population adopted the Greek culture, language and religion since the Mycenaean Greeks reached the island, nearly 3,500 years ago. Several migration waves shaped the population gene pool. Three minorities were formed, Armenians and Maronites who arrived in several waves after the 6th and 7th century AD, respectively, while the Latins represent the remnants of the catholic Francs during the reign of the Lusignan, 12th-15th century ([2]).
• Proto-Cypriots, settlers from Asia Minor, Middle and Near East, more than 12,000 years ago • Mycenaeans (1400–1300 BC), Achaeans (1230–1190 and 1150–1050 BC) • Phoenicians, 950–850 BC • Assyrians, 709–669 BC • Egyptians, 565–546 BC • Persians (fights with Cypriot kings Onisilos and Evagoras, Athenian Engagement and Persian Victory), 546–332 BC • Alexander the Great – Expulsion of the Persians, 332–323 BC • Ptolemies of Egypt, successors of Alexander the Great • Roman Empire, 58 BC • Byzantine Empire, 330 AD • Arab raids, 647–965 AD (Relocation to Artaki, 690 AD) • Crusaders, Richard Lionheart & Templars, 1191–1192 AD • Lusignan French, 1192–1474 AD • Venetians, 1474–1571 AD • Ottoman Empire, 1571–1878 AD • British Colonialism, 1878–1960 AD • Independence and accession of the new state to the British Commonwealth and the United Nations, 1960 AD • Accession to the European Union, 2004 • 1974, Invasion of Turkey, occupation of the nearly 37% northern part of the island • 1974–present, emigration to and from Cyprus, waves of foreign workers, whether citizens or non-citizens of the European Union

In the past 50 years, the Cypriot population has experienced major economic and lifestyle changes, due to major historical events and the economic crisis that has impacted especially the Eastern European countries in the past 10 years. Since the Turkish invasion in 1974, the population of Cyprus in the European non-occupied part of the island has increased from 648,585 to 923,272 individuals [3], not necessarily of Greek or Turkish origin. According to a 2021 census, the population of Cyprus altogether was estimated at 74% Greek Cypriots, including three small religious minorities of the Maronites, Armenians, and Latins, as well as Turkish Cypriots, altogether comprising about 1% of the population[3]. The population living in the northern part of the island under Turkish control, is estimated to be about 230,000. Despite the recent COVID-19 pandemic, life expectancy has only slightly changed between 2015 and 2021 (81.7 vs 81.2 years on average, respectively).

Chronic non-communicable diseases (NCDs), such as cardiovascular disease (CVD), diabetes, thyroid disorders, and cancer, pose a substantial health burden, significantly impacting morbidity and mortality rates. According to a 2018 report by the World Health Organization (WHO), NCDs accounted for over 90% of morbidity in Cyprus [4]. This prevalence of NCDs can be attributed to factors including lifestyle, dietary habits, and tobacco use. Also, genetic factors and gene-environment interactions contribute significantly to NCD development. Regional variation in NCDs has also been reported, suggesting the involvement of non-genetic factors that have yet to be identified. However, the presence of potential limitations in sample collection, such as the lack of representative samples and under-representation of specific regions may contribute to the fragmented understanding of NCD landscape in Cyprus [4]. From available information, cardiovascular disease is the primary cause of death amongst Cypriots, while the incidence of renal replacement therapy is 284 per million population, the highest in Europe [5].

Although most Cypriots declare a healthy status, two out of five suffer from a chronic disease, with CVD, cancer, and diabetes being the most prevalent conditions [6]. While CVD rates have been steadily decreasing since 2015, cancer rates remain at the same levels, albeit lower compared to the rest of the EU. On the contrary, tobacco use rates in Cyprus are amongst the highest in the EU, and together with unhealthy dietary habits, they comprise two of the most frequent mortality risk factors in Cyprus (19% and 14%, respectively) [6]. Additionally, while obesity rates in Cyprus are comparable to the average rates of other EU countries, childhood obesity is rapidly increasing and poses a significant public health issue for Cyprus.

To gain insights into the etiology and risk factors associated with NCDs and address limitations including the sampling of data from a diverse and representative population, the establishment of a Cypriot Biobank was imperative. While some causes of these diseases are already known based on studies conducted in other populations and regions [7, 8] current knowledge is insufficient to explain the substantial geographic differences in disease rates observed globally and within Cyprus itself [9]. The development of a Cypriot Biobank will enable large-scale studies of both genetic and environmental contributions, as well as their interactions, in the development of chronic diseases. Furthermore, it will address the limitations of previous studies, including inadequate sample sizes, lack of blood and/or urine samples, inconsistencies in data

collection and processing, limited data collection on risk exposures (e.g. lifestyle, diet, disease comorbidities) and outcomes, and restricted study populations.

The biobank.cy Center of Excellence (CoE) in Biobanking and Biomedical Research was established in 2019 at the University of Cyprus (UCY), after acquiring funding through the Horizon 2020 Widening Participation/Teaming program (Grant Agreement no. 857122). The program is a partnership of the UCY with two Advanced Partners, the European Biobanking consortium BBMRI-ERIC [10] and the Medical University of Graz [11] , and a local Partner, the medium-sized enterprise TALOS Rtd LTD [12] . Through this partnership, biobank.cy has successfully received funding to advance the country's medical research infrastructure to match European standards, with two major objectives: a) Upgrade the first Biobank of the country and complete the Cyprus Human Genome Project; b) build the capacity and upgrade its research infrastructure with the aim to prepare Cyprus for the next generation of biomedical research. For the history, biobank.cy is the result of upgrading the Molecular Medicine Research Center (MMRC) which was first established in 2010 with another strategic funding of the Regional Development Fund of the European Union and the Republic of Cyprus through the Cyprus Research Promotion Foundation, as part of the Smart Specialization Strategy of the country. In its current status, the Biobank is one of five Pillars of the biobank.cy CoE, the other four being, the MMRC as the research arm of the CoE, and the Molecular Diagnostics, the Education and Innovation pillars.

Towards the public health benefit and to support the development of the Cyprus Human Genome Project, the Government of Cyprus, and the University of Cyprus co-funded biobank.cy. As a first milestone, up to 16,500 permanent Cypriot residents will be invited to partake in the biobank cohort, voluntarily, until 2027. Data collection and storage includes baseline clinical, biochemical, and behavioral traits as well as blood and urine samples.

We herein provide comprehensive information on the operation of the first Biobank in Cyprus, sharing data on the demographics and health archives of participants.

Methods

Biobank setting

The biobank.cy, as an EU-funded CoE in Research and Innovation, hosts and maintains the Cyprus Biobank, which is not based in a hospital setting but enrolls volunteers who respond to open invitations while also collaborating with public and private clinics and ad hoc volunteer enrolment centers around the island. Operation of the Biobank in Cyprus is not regulated by a specialized law, although a legislation proposal regulating biobanks creation and operation is under consideration. There are national and EU laws regarding regulating the use of biological samples for research [13], the law providing for the protection of natural persons with regard to the processing of personal data and for the free movement of such data[14], the law for the establishment of the Cyprus National Bioethics Committee (CNBC)[15], and the EU GDPR 2016/679 law for the General Data Protection Regulation, which plays a significant role in emphasizing data protection principles, as the Biobank is in full compliance to its provisions[16]. These laws collectively ensure data protection, ethical standards, and informed consent in Biobank operations.

Approval for the operation of this first Biobank was first obtained by the CNBC in November 2011 (approval code: ΕΕΒΚ/ΕΠ/2011/04). The approved consent form allows for broad use of the data and material in Cyprus and abroad provided that any future research project secures its own separate ethics approval (English version of consent form is Supplementary Material_1).

Data collection and storage

The Biobank gathers information through a structured and comprehensive questionnaire, clinical phenotyping, and biological samples collected from Cypriot residents of the general population, aged ≥ 18 years old. Population data of the pilot study are collected and stored using REDCap® [17, 18] and OpenSpecimen® [19] tools respectively, to enable data security and tracking as well as to eliminate collection bias. Specifically, REDCap® (Research Electronic Data Capture) is a secure, web-based application designed for data collection and management in research studies, used to amass the following measurements: personal and family history as well as clinical (complete blood count, biochemical) and biometric (blood pressure, height, weight) (Supplementary Material_2). OpenSpecimen® is used as the Biobank's Information

151 Management System, by organizing information related to the collection, processing, storage, and
152 distribution of samples.

153 ***Participant/volunteer enrolment***

154 Since the very first enrollment on the 1st of November 2019, participant awareness and engagement in the
155 project were achieved through media and the press (television, radio, social media and newspapers, leaflets
156 respectively) as well as social events which are organized by the Biobank personnel. Additionally, friends and
157 family referrals were frequent throughout the 3-year period. Interested individuals book an appointment
158 either through the biobank.cy website [20] or directly through a phone call. At baseline, participants are
159 invited to the central collection point of the Biobank facility at the Shacolas Educational Center for Clinical
160 Medicine, or elsewhere during outreach activities, where they undergo a 3-stage interview (25 min on
161 average) and physical and clinical measurements (15 min on average) (Figure 1; Table 2). The Biobank
162 participation process commences with trained research nurses providing an initial briefing to the
163 participants. During this session, participants are fully informed about the research project's purpose, their
164 rights, and the procedures for participation and withdrawal, while they may ask questions about the project,
165 prior to signing a broad consent form. The consent form is approved by the Cyprus National Bioethics
166 Committee (approval code: ΕΕΒΚ/ΕΠ/2020/04), ensuring compliance with ethical requirements. A copy of
167 the signed consent form is given to the participant.

168 Upon completion of the informed consent process, participants are requested to fill out a questionnaire
169 providing essential information about their personal and family medical history. This information is securely
170 collected in dedicated REDCap® projects.

171 ***Health and lifestyle questionnaire administered by a trained research nurse***

172 In addition to data of personal character, the health and lifestyle section of the questionnaire includes
173 questions on socio-demographic factors, including the origin of both parents, medical conditions along with
174 medication used, family history and quality-of-life (QoL) questions, including smoking behavior, dietary
175 habits, alcohol consumption, intensity of physical activity [21] and sleeping patterns [22], education level and

176 employment status. As the questionnaire is part of the registration and clinic visit, a Biobank-trained research
177 nurse is always available to answer any questions of the participant.

178 Importantly, questions on dietary assessment are directly linked to the Mediterranean score (MedDietScore)
179 [23] which indicates the level of the participants' adherence to the traditional Mediterranean diet. This
180 specific type of diet has been widely used for the past ~20 years as it has been proven to significantly reduce
181 total mortality [24], thus having a great impact on clinical and public health. More specifically, a higher
182 MedDiet score showed strong evidence against incidents of cardiovascular disease, diabetes, hypertension,
183 obesity, and Alzheimer's disease among others [25]. Participants are specifically asked to report the
184 consumption frequency of whole grain food (bread, pasta, rice, etc), potatoes, fruit and juice, vegetables and
185 salads, legumes, fish and soup, red meat and its products/derivatives, poultry, full-fat dairy, and olive oil.

186



187 **Figure 1: Baseline visit summary**

188

Table 2: Instruments used at the Biobank for data measurements	
Measurement category	**Instrument**
Questionnaires	
Health & Lifestyle	Questions on socio-demographic factors, medical conditions, medication use, family history, smoking behavior, alcohol consumption, physical activity levels and sleeping patterns
Nurse Interview	Additional questions on QoL assessment (smoking, alcohol consumption, and physical activity frequency), family status, doctor-diagnosed conditions, education, employment status, and dietary patterns
Physical and clinical measurements	
Anthropometric	Height, weight, and waist circumference measurements*
Physiological	Blood pressure using a digital sphygmomanometer
Biological samples	
Biological samples collected	Whole peripheral blood, urine

**Waist circumference measures available for 960 individuals*

Physical-clinical measurements and biological material collected

At baseline, anthropometric and physiological traits were measured for each Biobank participant along with blood and urine sample collection. Anthropometric and physiological traits comprised body weight/height and diastolic/systolic blood pressure respectively. Blood pressure was measured once, in a seated position. A blood pressure measurement was repeated if the first measurement returned a value of >160mmHg for systolic blood pressure or <80 mmHg for diastolic blood pressure.

At the baseline enrolment visit, the participants provided peripheral blood for the isolation of DNA, plasma, and serum, which are stored at -80°C. Urine was also collected and aliquots were stored likewise. Specifically, we collected: 1x10ml EDTA for DNA extraction, 1x4ml EDTA for FBC, 1x4ml EDTA for plasma, 1x8.5ml serum, 1x3.5ml serum (prompt test), and 1x100ml urine. Aliquoted and stored are 4 aliquots of 50µl DNA at 50ng/µl, plus a concentrated DNA stock, 4 aliquots of 2ml serum, 2 aliquots of 1ml plasma, and 5 aliquots of 2ml urine.

Fifty-eight clinical biomarkers are measured by a private diagnostic provider using a proportion of the stored blood (Table 3). DNA concentration and quality are tested by spectrophotometric measurements and

203 calculation of the ratio at OD 260/280 and OD at 260/230. Urine is stored after a 5-minute centrifugation at
204 1000g at room temperature. The quality of frozen serum samples is assured in random retesting of selected
205 biochemical parameters.The Biobank employs a data curator who constantly and systematically tests for
206 quality assurance and consistency of data input to minimize errors and avoid bias. A comprehensive timeline
207 of biobanking and data/sample retrieval, with brief information on Standard Operating Procedures (SOPs)
208 and quality assurance measures applied throughout the procedure is provided in Figure 2. The detailed
209 standard operating procedures used at the Biobank are available on request.

Table 3: Clinical biomarkers measured at biobank.cy (N = 58)

Biomarker group	**Measure**	**Units**
Blood biochemistry		
Lipid profile	Total cholesterol	mg/dl
	Low-density lipoprotein (LDL)	mg/dl
	High-density lipoprotein (HDL)	mg/dL
	Triglycerides	mg/dL
Diabetes-related tests	Glucose	mg/dL
	Glycated Haemoglobin A1c %	%
Bone and joint markers	Uric acid	mg/dL
Complete Blood Count		
White blood cells	White blood cells	x10^3/μL
Differential white cell count	Lymphocytes	x10^3/μL
	Lymphocytes %	%
	Eosonophils	x10^3/μL
	Eosonophils %	%
	Monocytes	x10^3/μL
	Monocytes %	%
	Basophils	x10^3/μL
	Basophils %	%
	Neutrophils	x10^3/μL
	Neutrophils %	%
	LUC	x10^3/μL
	LUC %	%
Red blood cells	Haemoglobin	gr/dL

	Red blood cells	x10^6/µL
	Haematocrit	%
	Mean Corpuscular Hemoglobin (MCH)	pg
	Mean Corpuscular Hemoglobin Concentration (MCHC)	g/dL
	Mean Corpuscular Volume (MCV)	femtoliters (fL)
	Red Cell Distribution Width coefficient of variation (RDW CV)	%
	Haemoglobin Distribution Width (HDW)	%
Platelets	Platelets	10^3/mm^3
	Platelet Distribution Width (PDW)	%
	Mean Platelet Volume (MPV)	femtoliters (fL)
	Plateletcrit (PCT)	%
Urine Biochemistry by dipstick, and Microscopy		
Biochemistry	Protein	mg/dL
	Glucose	mg/dL
	Ketones	Negative/Positive
	Bilirubin	Negative/Positive
	Urobilinogen	mg/dL
	Nitrates	Negative/Positive
	Erythrocytes/Haemoglobin	Ery/µL
	Leucocytes	Leuco/µL
	Reaction (pH)	pH: 5-9
	Specific gravity	1,000 - 1030
Macroscopy	Appearance	
	Colour	
Microscopy	WBC (/hpf)	
	RBC (/hpf)	
	Epithelial cells	
	Casts	
	Casts Hyaline	
	Cast Granular	
	Crystals	
	Microorganisms	
	Yeasts	

Urine Biochemistry		
Microalbumin	Albumin	mg/L
	Microalbumin	mg/dl
	Urine Albumin/Creatinine ratio	mg/gr Creat
Protein/Creatinine Urine Ratio	Proteins	mg/dl
	Creatinine	mg/dl
	Urine Protein/Creatinine ratio	mg/gr Creat

210



Figure 2: Timeline of biobanking and data/sample retrieval, with brief information on SOPs and quality assurance measures applied throughout the procedure. The purple dots represent the quality assurance checkpoints and the blue dots represent the activities based on monitored SOPs.

Results

Sample size

We performed a power calculation using the "pwr" package in R software to estimate the required sample size for the Cypriot Biobank, based on a population of 923,372 individuals. The calculation was conducted using a 5% significance level and we adjusted for an expected response rate of 80%, which resulted in a required sample size of 480 individuals. In determining the sample size, we combined the power calculation with practical considerations. We accounted for factors such as the number of research nurses that would be hired, the expected number of participants per day after discussion with local clinicians and healthcare providers and the capacity of our facilities. Furthermore, we reviewed the approaches used by established biobanks to determine appropriate sample sizes. Burton et al[26], emphasize that biobanks intended for human genome epidemiology studies should consider using larger sample sizes to address potential heterogeneity in disease risk, enhance the precision of estimates, and improve sensitivity and specificity in diagnostic testing. Using this integrated approach of the theoretical sample size calculation, educated guesses and practical considerations, we estimated that a sample size of 16,500 individuals would be sufficient for the Biobank to be scientifically robust and operationally feasible. The pilot study enrolled 1348 participants not included in any disease-specific cohort of the Biobank, with a geographical distribution based on the father's origin (Figure 3).

Socio-demographic characteristics

The participants of the Biobank pilot study comprised 579 men (43%) and 769 women (57%) spanning an age range from 18-85 years, with a median age of 48 years (SD = 13.9 years) (Figure 4). More than half of men (n = 323 (55.8%)) and women (n = 420 (54.6%)) were educated to a university degree level and above, while the most frequent employment status for both men and women was paid employee (n = 358 (62%) and n = 486 (63%) respectively) (Table 4). The most common status of the enrolled individuals was either single or married (n = 282 (20.9%) and n = 981 (72.8%) respectively).



Figure 3: Geographical distribution of the 1348 participants of the pilot study, based on the origin of the father. The circle diameter reflects the density of the donors' enrolment in the corresponding area.



Figure 4: Age distribution of men and women enrolled in the Biobank pilot study

Table 4: Socio-demographic characteristics of the enrolled participants in the Biobank pilot study (November 2019 – October 2022). P-values for the comparison between sex groups were calculated using Chi-squared and Fisher's exact tests.

Characteristic	Men (%)	Women (%)	P-value
	579 (43)	769 (57)	
Age group (years)			0.29
< 25	22 (3.8)	30 (3.9)	
25-34	65 (11.2)	116 (15.1)	
35-44	135 (23.3)	163 (21.2)	
45-54	141 (24.4)	192 (25.0)	
≥ 55	216 (37.3)	268 (34.9)	
Marital status			0.01
Single	128 (22.1)	154 (20.0)	
Married	429 (74.1)	552 (71.8)	
Divorced	18 (3.1)	44 (5.7)	
Widowed	4 (0.7)	18 (2.3)	
Civil partnership	0 (0)	1 (0.1)	
Education			< 0.001
Lower than primary school	1 (0.1)	3 (0.4)	
Primary school	17 (2.9)	34 (4.4)	
Secondary school	161 (27.8)	167 (21.7)	
Technical/professional school	38 (6.6)	21 (2.7)	
College diploma (degree not equivalent to a BSc/BA)	39 (6.7)	124 (16.1)	
Bachelor's degree	200 (34.5)	261 (33.9)	
Master's degree	91 (15.7)	141 (18.3)	
PhD degree	32 (5.5)	18 (2.3)	
Employment status			< 0.001
Paid employee	358 (61.8)	486 (63.2)	
Self-employed	50 (8.6)	44 (5.7)	
Housewife	0 (0)	41 (5.3)	
Retired	87 (15.0)	76 (9.9)	
Unemployed	12 (2.1)	27 (3.5)	
Other	33 (5.7)	33 (4.3)	
Not reported	39 (6.7)	62 (8.1)	

263 *Medical history*

264 Based on the NHS and Heart UK guidelines (https://www.nhs.uk/conditions/high-cholesterol/cholesterol-
265 levels/), nearly half of the participants had high total (n = 681 (50.5%)) and LDL (n = 630 (46.7%)) cholesterol
266 levels. Additionally, 15.8% (n = 213) had low HDL levels and 19% (n = 257) had high triglyceride levels. Most
267 of these participants did not fast prior to the blood sample analysis. Among those with abnormal levels, only
268 151 out of 681 (22.2%) with high total cholesterol, 150 out of 630 (23.8%) with high LDL cholesterol, 31 out
269 of 213 (14.6%) with low HDL cholesterol, and 34 out of 257 (13.2%) with high triglyceride levels fasted before
270 the tests. The results of our pilot study are in line with recent findings regarding the high prevalence of
271 elevated blood lipid levels in the European population [27-29].

272 Even though most participants self-reported as healthy, a varying percentage had underlying past or current
273 conditions, with the most prevalent being hypertension (17.2%), osteoporosis (6.9%) and diabetes (6.0%)
274 (Figure 5). These findings are in line with OECD's research on the most common chronic conditions in Europe
275 for 2022 (https://health.ec.europa.eu/system/files/2022-12/2022_healthatglance_rep_en_0.pdf). As useful
276 as they are, they will prompt public policy decisions and enhance existing prevention programs. Additional
277 conditions recorded include cardiovascular disease (myocardial infarction and stroke), rheumatoid arthritis,
278 osteoarthritis, asthma, nephropathies, cancer and depression (Fig.4). Most individuals with a previously
279 diagnosed condition were under medication use (Table 5).



Figure 5: Diseases recorded among the participants of the pilot study

290

Table 5: Medical history and medication use (n = 1348). ǂThe disease is self-reported according to the doctor diagnosis.

Diseaseǂ **(ICD10CM)**		**Sex**		**Age group N (%)***					**Medication use**
	N_{total} (%)*	**N_{female} (%)***	**N_{male} (%)***	**<25**	**25-34**	**35-44**	**45-54**	**≥55**	N (%)
Hypertension (I10)	230 (17.2)	132 (57.4)	98 (42.6)	0 (0)	1 (0.4)	10 (4.3)	47 (20.4)	172 (74.8)	219 (95.2)
Myocardial Infarction (I21.-)	15 (1.1)	13 (86.7)	2 (13.3)	0 (0)	0 (0)	1 (6.7)	1 (6.7)	13 (86.7)	13 (86.7)
Stroke (I63.9)	12 (0.9)	6 (50.0)	6 (50.0)	0 (0)	1 (8.3)	2 (16.7)	2 (16.7)	7 (58.3)	10 (83.3)
Diabetes (E11.8)	80 (6.0)	43 (53.8)	37 (46.2)	0 (0)	0 (0)	5 (6.2)	23 (28.8)	52 (65.0)	78 (97.5)
Rheumatoid Arthritis (M06.9)	23 (1.7)	9 (39.1)	14 (60.9)	0 (0)	1 (4.3)	1 (4.3)	2 (8.7)	19 (82.6)	21 (91.3)
Osteoarthritis (M19.9)	31 (2.3)	9 (29)	22 (71)	0 (0)	0 (0)	3 (9.7)	4 (12.9)	24 (77.4)	29 (93.5)
Osteoporosis (M81.9)	93 (6.9)	13 (14)	80 (86)	0 (0)	1 (1.1)	3 (3.2)	19 (20.4)	70 (75.3)	86 (92.5)
Asthma (J45.90)	64 (4.8)	29 (45.3)	35 (54.7)	3 (4.7)	3 (4.7)	19 (29.7)	14 (21.9)	25 (39.0)	45 (70.3)
Nephropathies (N28.9)	33 (2.5)	20 (60.6)	13 (39.4)	2 (6.0)	1 (3.0)	9 (27.3)	4 (12.1)	17 (51.5)	27 (81.8)
Cancer (C00-C97)	24 (1.8)	10 (41.7)	14 (58.3)	0 (0)	1 (4.2)	0 (0)	3 (12.5)	20 (83.3)	7 (29.2)
Depression (F32.9)	22 (1.6)	3 (13.6)	19 (86.4)	0 (0)	2 (9.0)	7 (31.8)	5 (22.7)	8 (36.4)	17 (77.3)

291

* N_{total}(%) is the number of participants with the condition out of the total number of participants (n = 1348). N_{male}(%) and N_{female} (%) represent the number of males and females with the condition respectively, out of the total number of participants with the condition (N_{total}). Age group N(%) represents the number of participants with a condition by age group. Medication use N**(%)** indicates the number of participants under disease-specific medication use out of the total number of participants with the condition (N_{total}).

296 **Collaborations and perspectives**

297 The availability of the Biobank infrastructure has fostered collaborations with groups at national and
298 international Universities and Research Centers, including Europe and the USA. Sharing of data and material
299 is based on bipartite partnerships, either serving as custodians to data/sample archiving and storage or more
300 intimately involved in common research projects and grant writing. Signed Material Transfer
301 Agreement/Data Transfer Agreement (MTA/DTA) are in place, usually using our own approved documents.
302 State-of-the-art equipment, software and expertise in several fields such as biostatistics, epidemiology,
303 bioinformatics and genetics/genomics, have resulted in several important collaborations for massive genetic
304 analyses (Whole Exome Sequencing) of diverse disease cohorts (e.g. inherited kidney diseases, inherited
305 cardiomyopathies, traumatic brain injury). Also, the CYPROME data, based on 1000 Cypriot whole exomes,
306 that is now used to serve as the Cypriot reference genome, has already started being instrumental in
307 interpreting results from research projects and diagnostic services. Further infrastructure development
308 includes purchasing robotic systems for substantially increasing the results output and turnover, while
309 another larger server is pending for storing the Big Data generated in-house or through outsourcing and
310 collaborations. Finally, to maximize the use of samples and data, the Biobank personnel is also closely
311 engaged in research performing tasks.

312

313 **Discussion**

314 *The CY-Biobank*

315 The establishment of the first Biobank in Cyprus, in 2011, and its enhancement in 2019 as part of the
316 biobank.cy Center of Excellence, provides an opportunity for ground-breaking research both nationally and
317 internationally, through a rich collection of high-quality phenotypic data that will unveil the causes of
318 common and rare diseases affecting the Cypriot population. The data are retrieved from organized
319 questionnaires, the collection of blood and urine samples, and detailed clinical measurements. The Biobank
320 aims to reach a total sample size of 16,500 individuals by 2027 and intends to perform follow-up studies in a

321 sub-group of volunteers in the long-term to record disease progression, based on criteria to be determined.
322 After informed consent from the participants, the data is stored for research purposes with the goal to canvas
323 the architecture of the Cyprus human genome. biobank.cy is equipped with clinic, laboratory and liquid
324 sample storage facilities and offices for non-clinical research staff.

325 The Biobank was founded and launched as a national research infrastructure in 2011 with national and EU
326 funding and was significantly enhanced in 2019 through a Horizon 2020/Widening/Teaming Program, just
327 before the COVID-19 pandemic started. Despite the challenges and the relatively short period since its
328 establishment, it already has a high impact on the health of the Cypriot population. During the pandemic, in
329 addition to the original scope, biobank.cy collected samples from COVID-19 cases to study the production of
330 circulating immunoglobulin class G (IgG) antibodies against SARS-CoV-2 in the serum of convalescent
331 individuals [30]. Individuals who participated in the project received the results from their sample collection
332 two weeks later, thus gaining the opportunity to discuss potential abnormal ranges with their personal
333 doctors. The whole exome sequencing (WES) of 1500 convalescent participants in the project is pending.
334 Finally, notwithstanding the challenge of not being hosted at a hospital, we managed to turn it into an
335 opportunity by organizing outreach excursions to the periphery or at the premises of large enterprises and
336 organizations, for enrolling volunteers who would not easily reach us in Nicosia. It is of note that owing to
337 the small geography of the island, samples reach the Biobank within a maximum of two hours after
338 completion of the enrolments, by 2:00 pm the latest. This unrestricted enrolment strategy will enable the
339 design of epidemiological and other public health studies including the establishment of longitudinal cohorts
340 based on the data collected.

341 According to the data collected in this pilot study, volunteers diagnosed with hypertension represent 17.2%
342 of the general population, diabetics represent 6%, patients with osteoporosis represent 6.9%, and patients
343 with asthma represent 4.8%. With the understanding that these were not targeted patient groups, we
344 anticipate that with the systematic projected increase in participant recruitment, the Cypriot population will
345 soon be represented in greater depth which will validate and enhance our conclusions, with its separate
346 disease cohorts available for further research.

347 *Strategy and vision*

348 *Cyprus Human Genome Project*

349 biobank.cy was formed with the vision of being the island's central node for archiving high-quality biomaterial
350 and associated clinical records, with state-of-art research infrastructure facilities utilized for precision
351 medicine. Towards this goal, biobank.cy has launched the largest research study to ever run in Cyprus, with
352 the precise aim of understanding and treating diseases by characterizing the Cypriot genome. Specifically,
353 biobank.cy has initiated the Cyprus Human Genome Project (CHGP). This is the first in its kind of scale and
354 prospect study in Cyprus, with the aim of implementing Whole Exome Sequencing (WES) of 1000 Cypriots at
355 phase-1 and up to 5000 in the next 3 years. Also, Whole Genome Sequencing is a strategic objective. This
356 data will constitute the blueprint for the first Cypriot reference genome (CYPROME). Concurrently, additional
357 volunteers of the general population, including chronic disease patients, are selected for WES based on
358 additional ongoing separately funded research projects.

359 The establishment of the Biobank was a landmark development that enabled the materialization of the CHGP
360 as a significant milestone and a turning point for the health of the Cypriot population and precision medicine.
361 The CHGP will provide unprecedented insights in terms of the pathogenic variant load and disease prevalence
362 in the Cypriot population, while it will be of use to targeted epidemiological studies across all disciplines and
363 non-communicable disease investigations. Furthermore, the CHGP will provide the backbone to address
364 specific diseases on the island by documenting their prevalence and revealing putative environmental factors
365 that affect them. Moreover, biobank.cy with its increasing potential as a central medical research hub, will
366 provide an unsurpassable opportunity for Cypriot researchers and medical professionals to expand their
367 collaborations nationally and internationally while it will offer the opportunity to Cypriot patients to have
368 access to clinical trials and treatments not currently available in Cyprus.

369 Over the past 30+ years, genetic studies in the Cypriot population unraveled many interesting findings
370 concerning mainly rare diseases, including kidney conditions, neurological conditions, endocrinological
371 conditions and others [2]. Founder mutations were discovered for several diseases while a Cypriot consensus
372 whole genome sequence (including the non-coding part) is still lacking. The CHGP is promising to identify

more DNA variants of pathogenic potential and enable comparative studies in relation to the minor allele frequencies among the neighboring populations, thus leading to a better understanding of our genetic architecture.

Imminent Objectives

With regards to banking itself, a major effort is to increase the number of participants to cover the population to a greater depth, thereby empowering relevant epidemiological and genetics studies on all pathologies and enabling twin and population screening studies. To achieve our strategic objective of enrolling 16,500 participants by 2026 (now extended to 2027), as outlined in our EU-funded proposal, the Center of Excellence (CoE) has dedicated significant resources to raise awareness. Our Communication Office systematically organizes successful awareness campaigns using all available means, including social media, in full transparency. Additionally, the Biobank in collaboration with the Ethics, Legal, and Social Implications (ELSI) and Education Management, actively engages with local and regional authorities and the Human Resources departments of major enterprises. The Biobank organizes lectures, presentations, and exhibitions for young people at schools and other venues including our premises to promote biobanking and the research culture. Also, the campaigns proved effective in increasing the visibility of our website and online registration. These efforts, combined with providing engaging activities and educational material, aim to attract new volunteers to support our cause. An added value of these actions is achieving and strengthening public engagement and trust to the Biobank, preparing the next generation of citizens-scientists.

biobank.cy, since its inception, actively engages in Cyprus's eHealth ecosystem with a focus on becoming a fully operational eHealth Biobank. Aligned with Cyprus's 2019 eHealth law, it emphasizes citizen-centricity and interoperability. The core infrastructure includes a Biobank Information Management System (BIMS) serving as the nerve center for diverse health data, integrating clinical, sample, laboratory, genomic, and imaging data. The BIMS is designed for integration with the Cyprus's national EHR system, using the HL7 Fast Healthcare Interoperability Resources (FHIR) standard aiming to actively contribute to primary and secondary health data use. With a vision of becoming a key player in the Cyprus National and European Health Data Space, biobank.cy designs its infrastructure to become an early adopter of initiatives like International and

399 European Patient Summary while it already achieved integration with the BBMRI-ERIC Locator system using
400 HL7 FHIR.

401 In conclusion, as with any other Biobank, the Biobank of Cyprus is creating the prospects for next-generation
402 biomedical research. It is empowering investigations that include epidemiological and genetic determinants
403 with the aim to identify and evaluate the contribution of factors involved in major public health burdens
404 caused by primarily not communicable diseases.

405

406 **Acknowledgements**

407 This work was funded by the *CY*-Biobank, which is an EU Horizon 2020 Research and Innovation Programme
408 under Grant Agreement no. 857122, the Republic of Cyprus, and the University of Cyprus. The authors thank
409 the research nurses, Biobank technologists, and administrative personnel who contributed to making this
410 operation possible. The Biobank Directorship thanks all participants who voluntarily enrolled in the Biobank
411 and made this momentum task a reality for the health benefit of all.

412

413 **Author contributions**

414 Material preparation, participant recruitment, collection of biological material, and data collection were
415 performed with variable contributions of all authors. Statistical analyses were performed by EML. The first
416 draft of the manuscript was written by EML, CD, GP, AM, MK, ACK, MT, GC and SA and all authors commented
417 on the manuscript. All authors read and approved the final manuscript.

418 **Funding**

419 The biobank.cy pilot study was supported by *CY*-Biobank, an EU Horizon 2020 Research and Innovation
420 Programme under Grant Agreement no. 857122.

421 **Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author, upon a reasonable request.

DECLARATIONS

Ethics approval and consent to participate

Ethical approval was granted from the Cyprus National Bioethics Committee, code ΕΕΒΚ/ΕΠ/2011/04.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Voskarides, K., et al., *Y-chromosome phylogeographic analysis of the Greek-Cypriot population reveals elements consistent with Neolithic and Bronze Age settlements.* Investig Genet, 2016. **7**: p. 1.
2. Deltas, C., *The genetic heritage of Cypriots through special topics of genetics*. 2014, Athens: BHTA Medical Arts. 224.
3. Cyprus, S.S., *Census of population 2021.* 2021.
4. Charalampous, P., et al., *Burden of non-communicable diseases in Cyprus, 1990-2017: findings from the Global Burden of Disease 2017 study.* Arch Public Health, 2021. **79**(1): p. 138.
5. Boenink, R., et al., *The ERA Registry Annual Report 2019: summary and age comparisons.* Clin Kidney J, 2022. **15**(3): p. 452-472.
6. OECD, O.f.E.C.-o.a.D. *State Of Health In The EU* 2021; Available from: https://health.ec.europa.eu/system/files/2021-12/2021_chp_cyprus_cypriot.pdf.
7. Charalampous, P., et al., *Burden of non-communicable disease studies in Europe: a systematic review of data sources and methodological choices.* Eur J Public Health, 2022. **32**(2): p. 289-296.
8. Bai, J., et al., *Global Epidemiological Patterns in the Burden of Main Non-Communicable Diseases, 1990-2019: Relationships With Socio-Demographic Index.* Int J Public Health, 2023. **68**: p. 1605502.
9. Kyprianidou, M., et al., *Prevalence and sociodemographic determinants of selected noncommunicable diseases among the general population of Cyprus: A large population-based cross-sectional study.* Chronic Dis Transl Med, 2023. **9**(3): p. 222-237.
10. BBMRI-ERIC, *BBMRI-ERIC.* 2023.
11. Graz, M.U., *Medical University Graz.*
12. Talos, R., *RTD Talos.* 2023.
13. Government of Cyprus, P., *Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research*, in *Cyprus Parliament Archives*. 2023.
14. Government of Cyprus, P., *LAW PROVIDING FOR THE PROTECTION OF NATURAL PERSONS WITH REGARD TO THE PROCESSING OF PERSONAL DATA AND FOR THE FREE MOVEMENT OF SUCH DATA* Cyprus Parliament Archives, 2018.

15. Govenment of Cyprus, P., *The Bioethics (Establishment and Function of the National Committee) Law of 2001 enters into force with its publication in the Official Journal of the Republic of Cyprus in accordance with Article 52 of the Constitution.*, in *Cyprus Parliament Archives*. 2001.
16. Parliament, E., *REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation).* Official Journal of the European Union, 2016.
17. Harris, P.A., et al., *Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.* J Biomed Inform, 2009. **42**(2): p. 377-81.
18. Harris, P.A., et al., *The REDCap consortium: Building an international community of software platform partners.* J Biomed Inform, 2019. **95**: p. 103208.
19. Specimen, O., *Open Specimen.* 2023.
20. biobank.cy, *The CY-Biobank.* 2023.
21. Craig, C.L., et al., *International physical activity questionnaire: 12-country reliability and validity.* Med Sci Sports Exerc, 2003. **35**(8): p. 1381-95.
22. Roth, T., et al., *A new questionnaire to detect sleep disorders.* Sleep Med, 2002. **3**(2): p. 99-108.
23. Panagiotakos, D.B., et al., *MedDietScore: a computer program that evaluates the adherence to the Mediterranean dietary pattern and its relation to cardiovascular disease risk.* Comput Methods Programs Biomed, 2006. **83**(1): p. 73-7.
24. Trichopoulou, A., et al., *Adherence to a Mediterranean diet and survival in a Greek population.* N Engl J Med, 2003. **348**(26): p. 2599-608.
25. Guasch-Ferre, M. and W.C. Willett, *The Mediterranean diet and health: a comprehensive overview.* J Intern Med, 2021. **290**(3): p. 549-566.
26. Burton, P.R., et al., *Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology.* Int J Epidemiol, 2009. **38**(1): p. 263-73.
27. Timmis, A., et al., *European Society of Cardiology: Cardiovascular Disease Statistics 2017.* Eur Heart J, 2018. **39**(7): p. 508-579.
28. Laufs, U., et al., *Why is hypercholesterolaemia so prevalent? A view from evolutionary medicine.* Eur Heart J, 2019. **40**(33): p. 2825-2830.
29. Steinhagen-Thiessen, E., et al., *Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS).* Cardiovasc Diabetol, 2008. **7**: p. 31.
30. Mamais, I., et al., *Circulating IgG Levels in SARS-CoV-2 Convalescent Individuals in Cyprus.* J Clin Med, 2021. **10**(24).